A new class of safer pain relievers
Arylepoxamides: A new class of potent, safer analgesics
This study is testing a new type of pain relief medication called MP1000, which aims to help people manage pain without the risks of addiction that come with traditional opioids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sparian Biosciences, INC. NIH-funded |
| Lab location | 1 site (New York City, United States) |
| Project ID | NIH-10690777 on NIH RePORTER |
What this research studies
This research investigates a novel class of analgesics called arylepoxamides, which target a unique site in the brain to provide pain relief without the addictive side effects associated with traditional opioids. The approach aims to reduce opioid prescriptions and their associated risks by developing a compound, MP1000, that effectively alleviates pain from various sources while avoiding respiratory depression and dependence. The research includes preclinical studies and plans for a Phase 1 clinical trial to evaluate the safety and efficacy of this new pain medication.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from chronic pain who are currently using opioids or are seeking alternative pain relief methods.
Not a fit: Patients who do not experience chronic pain or those who are not currently using opioids may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer pain management options that reduce reliance on opioids and lower the risk of addiction.
How similar studies have performed: Other research has shown promise in developing non-opioid analgesics, but this specific approach with arylepoxamides is novel and untested in clinical settings.
Where this research is happening
New York City, United States
- Sparian Biosciences, INC. — New York City, United States (Active)
Researchers
- Principal investigator: Reich, Jeffrey — Sparian Biosciences, INC.
- Study coordinator: Reich, Jeffrey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.